Suppr超能文献

化疗敏感性和DNA含量作为卵巢癌的预后因素:初步结果

Chemosensitivity and DNA content as prognostic factors in ovarian cancer: preliminary results.

作者信息

Prosperi Porta R, Rulli G, Giovagnoli M R, Carenza L

机构信息

II Department of Obstetrics and Gynaecology, University of La Sapienza, Rome.

出版信息

Eur J Gynaecol Oncol. 1990;11(2):91-6.

PMID:2379519
Abstract

Fourteen samples of epithelial ovarian cancer were studied; chemosensitivity in vitro was examined by clonogenic assay, and DNA content was measured by static cytometry. Seven cases were aneuploid. The average survival of the diploid cases was almost twice that of the aneuploid cases (21 vs 11 months). Five of the 7 diploid, and 4 of the aneuploid cases were chemosensitive in vitro; 4 diploid and 3 aneuploid tumors were sensitive in vivo. The vitro/vivo correlation was positive for 6 out of 7 aneuploid tumors, and for 4 out of 7 diploid cases. Patients sensitive in vitro to at least one of the two drugs tested responded more often to chemotherapy, whatever drugs were used in vitro. The patients whose 5 C exceeding rate was 10% survived 12 months at most, with an average survival of 8 months; patients with a low aneuploidy index survived an average of 20 months. The behavior of the diploid tumors in vitro was more varied. Ploidy would seem to be an additional factor to other parameters of prognosis, while no correlation is evident between chemosensitivity in vitro, D.I., and 5 C exceeding rate.

摘要

对14例上皮性卵巢癌样本进行了研究;通过克隆形成试验检测体外化疗敏感性,通过静态细胞术测量DNA含量。7例为非整倍体。二倍体病例的平均生存期几乎是非整倍体病例的两倍(21个月对11个月)。7例二倍体病例中有5例,非整倍体病例中有4例在体外对化疗敏感;4例二倍体和3例非整倍体肿瘤在体内敏感。7例非整倍体肿瘤中有6例、7例二倍体病例中有4例体外/体内相关性为阳性。无论体外使用何种药物,体外对至少两种测试药物之一敏感的患者对化疗的反应更频繁。5C超过率为10%的患者最多存活12个月,平均生存期为8个月;非整倍体指数低的患者平均存活20个月。二倍体肿瘤在体外的表现更为多样。倍性似乎是预后其他参数之外的一个附加因素,而体外化疗敏感性、D.I.和5C超过率之间没有明显相关性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验